3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

You may be eligible if

• Histologically confirmed diagnosis of 1 of the following hematologic malignancies:
• * Relapsed or refractory acute myeloid leukemia (AML)
• * Relapsed or refractory acute lymphoblastic leukemia
• * Secondary AML, including AML arising from antecedent hematologic diseases, such as myelodysplastic syndromes or myeloproliferative disorders OR therapy-related AML
• * Chronic myeloid leukemia in accelerated or blast phase
• Refractory to standard therapy or no standard therapy exists
• No known brain metastases
• Performance status - CALGB 0-2
• Performance status - Karnofsky 60-100%
• No G6PD deficiency
• Bilirubin \< 2.0 mg/dL (unless due to Gilbert's syndrome)
• AST and ALT \< 2.5 times upper limit of normal (ULN)
• Creatinine \< 1.5 times ULN
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No pulmonary disease requiring oxygen
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior allergic reactions attributed to compounds of similar chemical or biological composition to study drugs
• No neuropathy
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No other concurrent uncontrolled illness
• No concurrent biologic agents
• At least 72 hours since prior hydroxyurea
• At least 2 weeks since other prior chemotherapy (6 weeks for mitomycin or nitrosoureas)
• No other concurrent chemotherapy
• At least 2 weeks since prior radiotherapy
• No concurrent radiotherapy
• Recovered from all prior therapy
• At least 4 weeks since prior investigational agents
• No other concurrent investigational therapy
• No other concurrent anticancer therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients